Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jun 24, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid said this week that it has tapped Robert Kwiatkowski to be its VP of infectious disease research and development. Kwiatkowski has worked in nucleic acid infectious disease test development at Siemens Healthcare Diagnostics, Gentra Systems, Third Wave Technologies, Becton Dickinson Molecular Diagnostics, and Digene Diagnostics.

HTG Molecular Diagnostics has appointed Debra Gordon to be its VP, chief legal counsel. Gordon will lead the development and execution of the company's intellectual property strategy, its human resources activities, and advise on legal matters. She previously was general counsel and head, patent legal for Ventana Medical Systems.

Pressure Biosciences has elected Jeffrey Peterson to serve on its board of directors in a newly created spot through the 2012 annual shareholders meeting. Peterson currently is CEO of Target Discovery, where he has worked for 12 years, and he formerly was CEO and GM of Abbott South Africa, and spent 11 years with General Electric's Engineered Materials and Plastics businesses. Peterson was elected contingent on the purchase of an aggregate of at least $500,000 of units in a private placement this past week by Clayton Struve.

Portable PCR testing systems developer InstantLabs has named Neil Sharma to be director of product development. In the new position, Sharma will oversee the advancement of the firm's pipeline of assays and will focus on medical diagnostic and food safety applications. Sharma recently worked at Qiagen, where he was involved in placing and integrating RT-PCR and sequencing-based tools into clinical and research labs. He also has worked at Genomic Solutions and Biotage.

AtheroNova has appointed Ephraim Sehayek of Cleveland Clinic to its scientific advisory board. At Cleveland Clinic, Sehayek is on staff at the Genomic Medicine Institute of the Lerner Research Institute. He also is an assistant professor of molecular medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

BioNanomatrix has named Todd Dickinson vice president of product development and Xing Yang vice president of system integration, as part of an expansion that included opening up a San Diego office. Dickinson joined BioNanomatrix from Illumina, where he most recently served as director of product development for Illumina's DNA sequencing business. Yang joined BioNanomatrix from San Diego-based Epic Sciences, which he co-founded and for which he served as vice president of technology. He also was president of research for Helixis and director of systems development for BD Diagnostics-GeneOhm.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.